Latest Administration News

Imricor Medical Systems has submitted the third of four Premarket Approval modules to the FDA, marking a key step towards US approval of its MR-guided cardiac ablation devices.

Freedom Bidco, Inc. has launched a non-binding cash proposal to acquire all Strata shares at A$0.16 each, matching the last traded price before suspension and offering shareholders a rare liquidity event ahead of Strata's expected ASX delisting.

A new geophysical survey at EV Resources’ Los Lirios project in Mexico reveals extensive sulphide anomalies and a structural fault network, significantly expanding the exploration footprint and sharpening drill targets ahead of a maiden resource estimate.

Antilles Gold’s Cuban joint venture Minera La Victoria has been hit with US sanctions, prompting a suspension of the company’s direct involvement and halting trading of its shares and options.

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Urbanise.com Limited is poised to transform the Australian strata sector with a staged pilot release of its enhanced Strata platform, integrating NAB banking services and launching a branded owners portal from July 2026.

Imugene’s off-the-shelf CAR T therapy azer-cel has won FDA Fast Track Designation for relapsed or refractory CLL/SLL and MZL, backed by compelling Phase 1b response rates.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

Alterity Therapeutics has clinched FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy, with the trial set to begin by the end of 2026.

Perpetual Limited is set to acquire a majority stake in loan servicing technology firm Interfi Systems, enhancing its Corporate Trust division’s digital capabilities while targeting a 15% reduction in gross debt by June 2026.

Urbanise is set to launch a unified strata payments platform integrated with NAB banking, promising streamlined workflows and a branded owners portal from July 2026.

Opthea Limited resumes ASX trading as it pivots to develop OPT-302 for lymphangioleiomyomatosis, outlining a disciplined 18-month staged clinical program backed by A$31.2 million in cash.